[
    {
        "molecule_name": "antibody or antibody fragment",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "affinity",
        "value": "10^10 M to 10^12 M",
        "unit": "M",
        "raw_mentions": "According to some embodiments, the mAb binds to human EMMPRIN that comprises at least one post- translational modification present in normal cells expressing EMMPRIN, but not in pathologic cells, with a Kd of at least two orders of magnitude higher than the Kd for binding to pathologic cells.\nAccording to some embodiments, the antibody or antibody fragment binds to human EMMPRIN on pathogenic cells or tissue with affinity at the range of 10'^10 M to 10'^12 M and to human EMMPRIN on normal cells or tissue with affinity at the range of 10'^6 M tolO'^10 M or with affinity at the range of 10'^6 M tolO'^8 M."
    },
    {
        "molecule_name": "antibody or antibody fragment",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "affinity",
        "value": "10^6 M to 10^10 M or 10^6 M to 10^8 M",
        "unit": "M",
        "raw_mentions": "According to some embodiments, the mAb binds to human EMMPRIN that comprises at least one post- translational modification present in normal cells expressing EMMPRIN, but not in pathologic cells, with a Kd of at least two orders of magnitude higher than the Kd for binding to pathologic cells.\nAccording to some embodiments, the antibody or antibody fragment binds to human EMMPRIN on pathogenic cells or tissue with affinity at the range of 10'^10 M to 10'^12 M and to human EMMPRIN on normal cells or tissue with affinity at the range of 10'^6 M tolO'^10 M or with affinity at the range of 10'^6 M tolO'^8 M."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "1",
        "unit": "pM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "100",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "50",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "40",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "30",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "20",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "10",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "5",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "2",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "1",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "0.5",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "0.1",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "0.05",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "0.01",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "0.001",
        "unit": "nM",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "<10^-8",
        "unit": "M",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "from 10^-8 to 10^-13",
        "unit": "M",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "antibody",
        "protein_target_name": "human EMMPRIN",
        "binding_metric": "Kd",
        "value": "from 10^-9 to 10^13",
        "unit": "M",
        "raw_mentions": "In some embodiments, an antibody provided herein has a dissociation constant (Kd) of about 1 pM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10<sup>-8</sup> M or less, e.g., from 10<sup>-8</sup> M to 10<sup>-13</sup> M, e.g., from 10<sup>-9</sup> M to 10“<sup>13</sup> M) for human EMMPRIN."
    },
    {
        "molecule_name": "hMR18-mAb",
        "protein_target_name": "EMMPRIN",
        "binding_metric": "Kd",
        "value": "5.9xlO'5",
        "unit": "pM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nKd values of the hMR18-mAb to the EMMPRIN protein expressed on human cancer cells (the renal carcinoma A498 and breast carcinoma MDA-MB-231 cell lines) were compared with its Kd values to the EMMPRIN protein expressed on the human primary fibroblast-like synoviocytes (FLS) obtained from a joint of a RA patient, Kd=5.9xlO'<sup>5</sup>pM (10'<sup>11</sup> M) or 6.4xl0'<sup>5</sup> pM (10'<sup>11</sup> M) for MDA- MB-231 and A498 cells, respectively, relative to Kd=5.4xl0'<sup>3</sup> pM (10‘<sup>9</sup> M) for the FLS cells.\nIn comparison, a commercial anti-EMMPRIN antibody (from Biolegend), showed the same range of Kd values (Kd=1.3-1.9xl0‘<sup>4</sup> pM (IO'<sup>10</sup> M) for all cells used, including the non- cancerous cells (Figure 4B)."
    },
    {
        "molecule_name": "hMR18-mAb",
        "protein_target_name": "EMMPRIN",
        "binding_metric": "Kd",
        "value": "6.4xl0'5",
        "unit": "pM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nKd values of the hMR18-mAb to the EMMPRIN protein expressed on human cancer cells (the renal carcinoma A498 and breast carcinoma MDA-MB-231 cell lines) were compared with its Kd values to the EMMPRIN protein expressed on the human primary fibroblast-like synoviocytes (FLS) obtained from a joint of a RA patient, Kd=5.9xlO'<sup>5</sup>pM (10'<sup>11</sup> M) or 6.4xl0'<sup>5</sup> pM (10'<sup>11</sup> M) for MDA- MB-231 and A498 cells, respectively, relative to Kd=5.4xl0'<sup>3</sup> pM (10‘<sup>9</sup> M) for the FLS cells.\nIn comparison, a commercial anti-EMMPRIN antibody (from Biolegend), showed the same range of Kd values (Kd=1.3-1.9xl0‘<sup>4</sup> pM (IO'<sup>10</sup> M) for all cells used, including the non- cancerous cells (Figure 4B)."
    },
    {
        "molecule_name": "hMR18-mAb",
        "protein_target_name": "EMMPRIN",
        "binding_metric": "Kd",
        "value": "5.4xl0'3",
        "unit": "pM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nKd values of the hMR18-mAb to the EMMPRIN protein expressed on human cancer cells (the renal carcinoma A498 and breast carcinoma MDA-MB-231 cell lines) were compared with its Kd values to the EMMPRIN protein expressed on the human primary fibroblast-like synoviocytes (FLS) obtained from a joint of a RA patient, Kd=5.9xlO'<sup>5</sup>pM (10'<sup>11</sup> M) or 6.4xl0'<sup>5</sup> pM (10'<sup>11</sup> M) for MDA- MB-231 and A498 cells, respectively, relative to Kd=5.4xl0'<sup>3</sup> pM (10‘<sup>9</sup> M) for the FLS cells.\nIn comparison, a commercial anti-EMMPRIN antibody (from Biolegend), showed the same range of Kd values (Kd=1.3-1.9xl0‘<sup>4</sup> pM (IO'<sup>10</sup> M) for all cells used, including the non- cancerous cells (Figure 4B)."
    },
    {
        "molecule_name": "anti-EMMPRIN antibody",
        "protein_target_name": "EMMPRIN",
        "binding_metric": "Kd",
        "value": "1.3-1.9xl0'4",
        "unit": "pM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nKd values of the hMR18-mAb to the EMMPRIN protein expressed on human cancer cells (the renal carcinoma A498 and breast carcinoma MDA-MB-231 cell lines) were compared with its Kd values to the EMMPRIN protein expressed on the human primary fibroblast-like synoviocytes (FLS) obtained from a joint of a RA patient, Kd=5.9xlO'<sup>5</sup>pM (10'<sup>11</sup> M) or 6.4xl0'<sup>5</sup> pM (10'<sup>11</sup> M) for MDA- MB-231 and A498 cells, respectively, relative to Kd=5.4xl0'<sup>3</sup> pM (10‘<sup>9</sup> M) for the FLS cells.\nIn comparison, a commercial anti-EMMPRIN antibody (from Biolegend), showed the same range of Kd values (Kd=1.3-1.9xl0‘<sup>4</sup> pM (IO'<sup>10</sup> M) for all cells used, including the non- cancerous cells (Figure 4B)."
    }
]